What are some names for basal insulin?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 14, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Names of Basal Insulin

Basal insulin options include NPH, glargine, detemir, and degludec, which are designed to provide a relatively constant level of insulin to control blood glucose between meals and overnight. 1

Types of Basal Insulin

Human Basal Insulin

  • NPH (Neutral Protamine Hagedorn) - an intermediate-acting human insulin that may be administered once or twice daily 1

Long-Acting Insulin Analogs

  • Insulin glargine (U-100 and U-300 formulations)

    • Brand names: Lantus (U-100), Toujeo (U-300) 1, 2
    • Once-daily administration 1
  • Insulin detemir

    • Brand name: Levemir 1, 3
    • May require once or twice-daily administration 1, 4
  • Insulin degludec

    • Brand names: Tresiba (available as U-100 and U-200 formulations) 1, 5
    • Ultra-long-acting with duration >42 hours 6
    • Once-daily administration 1

Characteristics of Basal Insulins

Mechanism of Action

  • Basal insulins are designed to cover the body's basal metabolic insulin requirement by primarily regulating hepatic glucose production 1
  • They provide relatively constant insulin levels without pronounced peaks, unlike prandial (mealtime) insulins 2

Pharmacodynamic Differences

  • NPH insulin has a more pronounced peak and shorter duration compared to long-acting analogs 1
  • Long-acting analogs (glargine, detemir, degludec) have flatter profiles with less within-patient variability 6, 7
  • Insulin degludec forms multi-hexamers when injected subcutaneously, resulting in an ultra-long duration of action 5

Clinical Considerations

  • Long-acting insulin analogs generally have a lower risk of nocturnal hypoglycemia compared to NPH insulin 1, 2
  • Insulin detemir is associated with less weight gain compared to insulin glargine, but may require higher doses and twice-daily administration in some patients 4
  • Insulin degludec offers the potential for flexible dosing due to its ultra-long duration of action 6

Dosing Considerations

  • Basal insulin is typically initiated at 10 units or 0.1-0.2 units/kg/day, depending on the degree of hyperglycemia 1
  • Dose adjustments are made based on fasting blood glucose levels 1
  • Some patients may require twice-daily dosing with certain basal insulins (particularly NPH and sometimes detemir) 1, 4

Practical Considerations

  • Basal insulin is often the first insulin added to oral medications when initiating insulin therapy in type 2 diabetes 1
  • It is typically used in combination with metformin and possibly one additional non-insulin agent 1
  • When basal insulin alone doesn't achieve glycemic targets, additional prandial insulin or GLP-1 receptor agonists may be added 1

Human Insulin Therapy

AI: I need to provide a comprehensive answer about basal insulin names and types. Let me organize this information clearly.

First, I'll identify the main categories of basal insulins:

  1. Human basal insulin (NPH)
  2. Long-acting insulin analogs (glargine, detemir, degludec)

For each, I'll provide:

  • Generic names
  • Brand names when available
  • Basic characteristics
  • Dosing considerations

I'll structure this with clear headings and bullet points, making sure to cite evidence for each point.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Insulin glargine (Lantus).

International journal of clinical practice, 2002

Research

Insulin detemir: a long-acting insulin product.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2006

Research

Insulin detemir versus insulin glargine for type 2 diabetes mellitus.

The Cochrane database of systematic reviews, 2011

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.